Emmes supports new collaboration to advance COVID-19 research for children

pharmafile | February 4, 2022 | News story | Medical Communications  

Clinical research organisation, Emmes, announced its role as a Data Coordinating Center on a team whose work has accelerated paediatric COVID-19 research.

The team, led by the Paediatric Trials Network at Duke University, also includes the Gabriella Miller Kids First Data Resource Center (DRC), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD).

The Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children per Standard of Care (POP02), is one of several studies within the Collaboration to Assess Risk and Identify LoNG-term outcomes for Children with COVID, known as CARING for Children with COVID.

The programme aims to provide information to help healthcare providers and parents make informed decisions when caring for children infected with either COVID-19, or who have MIS-C (multisystem inflammatory syndrome).

Valerie Cotton, deputy director of the Office of Data Science and Sharing at NICHD, said, “Rapidly sharing paediatric COVID-19 data using interoperability standards accelerates research that will help understand the impact of the pandemic on children and design interventions.  This effort is a model for how groups can collaborate to respond to public health needs.”

“Our role as Data Coordination Center for the Best Pharmaceuticals for Children Act dates back to 2009,” noted Emmes CEO, Dr Christine Dingivan.  “Now, with this newer work, we’ve widened our focus from supporting the safe drug development in children to the international priority on how to combat paediatric COVID-19.”

Lina Adams

Related Content

No items found

Latest content